Dose response curves of diamide, GSSG, and H 2 O 2 after 5 min incubation with recombinant hGrx1-roGFP2
To view or add a comment, sign in Liver cancer often develops in the setting of lipotoxicity, where excess fat builds up in the liver, triggering inflammation, metabolic stress, and changes in blood vessel growth
Its pathogenesis has been characterized by the production of antinuclear autoantibodies (ANA) with both T cells 2 and B cells being essential for disease development 3,4
Zhao J, et al
Traditional formulations often suffer from issues like: Poor encapsulation of sensitive or water-repelling (hydrophobic) actives Inconsistent particle size, leading to unpredictable bioavailability and targeting Rapid degradation or leakage, resulting in short shelf life Difficulties maintaining performance when scaling from lab to production Liposome encapsulation solves these problems by: Maximizes absorption, especially for oral and topical delivery Extends circulation time for longer therapeutic effect Minimizes toxicity through targeted or controlled release Shields fragile actives such as mRNA, enzymes, and probiotics from degradation At BOC Sciences, we address these obstacles head-on through advanced liposome encapsulation technology
